Brief: Nuvation Bio Announces Acquisition Of Japan Rights To Safusidenib From Daiichi Sankyo
01/04/2026 14:11
April 1 (Reuters) - Koge Micro Tech Co Ltd 4568.TWO: NUVATION BIO ANNOUNCES ACQUISITION OF JAPAN RIGHTS TO SAFUSIDENIB FROM DAIICHI SANKYO NUVATION BIO INC - BUYS JAPAN RIGHTS TO SAFUSIDENIB FROM DAIICHI SANKYO NUVATION BIO INC - GAINS OWNERSHIP OF GLOBAL CLINICAL DEVELOPMENT PROGRAM FOR SAFUSIDENIB NUVATION BIO INC - TO EXPAND PIVOTAL SIGMA STUDY OF SAFUSIDENIB INTO JAPAN Source text: ID:nPn25pYNSa Further company coverage: 4568.TWO ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nuvation Bio
See all newsBrief: Nuvation Bio To Expand Pivotal Phase 3 Sigma Study Of Safusidenib For Idh1-Mutant Glioma To Six European Countries
Brief: Nuvation Bio To Report Third Quarter 2026 Financial Results And Provide Business Update On November 4, 2026
U.S. RESEARCH ROUNDUP-Everpure, Marvell Technology, Okta
Nuvation Bio Inc. reports results for the quarter ended June 30 - Earnings Summary
Nuvation Bio Q2 revenue beats estimates on IBTROZI growth